



## Latest oncology clinical development updates

Wednesday, March 19, 2025

[Subscribe here](#)

[Read this newsletter online](#)

### OTW News Highlights this week

- [Positive Topline Results from Ph 3 VERITAC-2 Clinical Trial Announced](#)
- [2seventy bio Enters into Definitive Agreement to be Acquired by BMS](#)
- [Dosing Completed in the First Cohort of Ph 1 Study of NKT3964](#)
- [Positive Topline Result for TEDOPaM Ph 2 trial of OSE2101 \(Tedopi\) in Advanced Pancreatic Cancer Announced](#)
- [FDA approves IND application to initiate Oncorella-1 Ph 1/2 trial of ONC175](#)
- [Penpulimab Receives NMPA Approval for 1L Treatment of Nasopharyngeal Cancer](#)
- [AstraZeneca enters license agreement with Alteogen for subcutaneous formulations of multiple oncology assets](#)
- [Multikine Confirmatory Ph 3 Trial in newly diagnosed locally advanced head and neck cancer patients to be Initiated](#)
- [SGO 2025: ELAHERE \(mirvetuximab soravtansine-gynx\) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients](#)
- [FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC](#)

- [Imfinzi approved in the EU for limited-stage SCLC](#)



#### [NMPA approves Sacituzumab Tirumotecan \(sac-TMT\) for EGFRm NSCLC](#)


Dr. Michael Ge, CEO of Kelun-Biotech said, "We are very pleased that the second indication of the Company's TROP2 ADC sacituzumab tirumotecan has been approved for marketing, which is exciting progress for us in the field of lung cancer. The successful approval of this new indication will help to address an unmet treatment need for patients with later-stage EGFRm NSCLC ...

---

#### [European Commission approved Expanded Use of Breyanzi for R/R Follicular Lymphoma](#)

“This additional approval for Breyanzi in FL represents a critical step forward in our mission to deliver on the transformational promise of cell therapy for more patients across Europe,” said Emma Charles, senior vice president, Europe Region, Bristol Myers Squibb. “While significant advancements have been made in the last two decades, there still remains unmet need for patients. Newer treatments ...

[Read more Drug Approvals](#)



### [Update relating to Resminostat's \(Kinselby\) Marketing Authorisation Application announced](#)

Jason Loveridge, Ph.D., CEO of 4SC, commented: “This filing marks a significant step forward for resminostat (Kinselby) as we progress ever closer to marketing authorisation approval, which is expected in mid-2025. We remain committed to bringing this much needed treatment to patients as soon as possible, and preparations for market launch are ongoing, as well as actively engaging with potential ...

---

### [EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer](#)

Reagan Jarvis, co-founder and Chief Executive Officer, commented, “This approval is a significant step in Anocca’s development as we transition to a clinical-stage company. Our highly skilled team is focused on discovering, optimising and manufacturing innovative next generation treatments that harness T-cell immunity and ANOC-001 represents the first of many products that will advance to the clinic in the coming ...

[Read more Regulatory News](#)



### [Actimab-A + CLAG-M Trial Results in Patients with R/R AML published in the Journal Leukemia](#)


Sandesh Seth, Actinium's Chairman and CEO, said, "There is significant momentum for Actimab-A with the publication of these positive results in Leukemia and the recent initiation of the frontline AML triplet combination with Venetoclax and the hypomethylating agent ASTX-727 under our NCI CRADA. Actinium is committed to addressing the needs of the over 100,000 patients with AML and MDS in ...

---

### [Updated 18-Month DOR of 80.6% from Ph 3 ENVISION Trial of UGN-102 Announced](#)

"2024 was a pivotal year for UroGen with achievements across our commercial business and pipeline," said Liz Barrett, President and Chief Executive Officer of UroGen. "The progress with UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer, including completion of the submission of our NDA ahead of schedule and compelling DOR data from the Phase 3 ENVISION trial, further positions us ...


[Read more Trial Results](#)



### [Metastatic breast cancer indication to be pursued for \(Z\)-endoxifen](#)

Dr. Steven Quay, Chairman and Chief Executive Officer of Atossa Therapeutics, stated: "Our decision to advance (Z)-endoxifen into a metastatic breast cancer indication underscores our unwavering commitment to developing a best-in-class therapy for women facing this devastating disease. The encouraging clinical data that has been generated to date supports the potential of (Z)-endoxifen to provide a meaningful benefit to patients ...

[Read more Trial Status](#)



### [iOncologi, Inc. Acquires TargImmune Therapeutics to Expand and Strengthen Immunotherapy Pipeline Against Solid Tumors](#)

"This acquisition represents a pivotal moment for iOncologi as we continue to push the boundaries of immunotherapy for solid tumors," said Dr. Edgardo Rodriguez-Lebron, iOncologi's recently appointed CEO. "TargImmune's pioneering approaches perfectly align with our mission to develop transformative cancer therapies. By integrating two incredibly talented and highly experienced drug development teams, we are well-positioned to accelerate innovation and bring ...

---

### [AstraZeneca to acquire EsoBiotec to advance cell therapy ambition](#)

Susan Galbraith, Executive Vice President, Oncology Haematology R&D, AstraZeneca, said: "We are excited about the acquisition of EsoBiotec and the opportunity to rapidly

advance their promising in vivo platform. We believe it has the potential to transform cell therapy and will enable us to scale these innovative treatments so that many more patients around the world can access them. EsoBiotec ...

[Read more Business News](#)

## Editor's Desk

### Editor's Desk

#### Author

- [Richa Tewari, PhD](#)

#### Managing Editors

- [Shalini Roy Choudhury, PhD](#)
- [Anusha Jayaraman, PhD](#)

#### Social Media Managers

- [Siftjit Kaur, PhD](#)
- [Himanshi Agarwal, PhD](#)



*Disclaimer:* The OTW team take care to share authentic information. In case of any discrepancies please write to [newsletter@onco-this-week.com](mailto:newsletter@onco-this-week.com). Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is a part of RLS Consultants, which is a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have

any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.